Evolent Health (EVH) Receivables (2015 - 2026)

Evolent Health's Receivables history runs 12 years deep, the most recent figure standing at $315.0 million for Q1 2026.

• On a quarterly basis, Receivables fell 28.52% year-over-year to $315.0 million in Q1 2026; TTM through Mar 2026 was $315.0 million, a 28.52% decrease from a year earlier, with the FY2025 full-year figure at $311.0 million, down 26.12% from the prior year.
• Receivables improved to $315.0 million in Q1 2026 per EVH's latest filing, from $311.0 million in the prior quarter.
• Across five years, Receivables topped out at $472.4 billion in Q4 2023 and bottomed at $127.7 million in Q2 2022.
• The 5-year median for Receivables is $366.2 million (2023), against an average of $28.1 billion.
• Across the five-year window, Receivables surged 175429.54% in 2023 and plunged 99.91% in 2024, its largest moves.
• Year by year, Receivables stood at $269.1 million in 2022, then jumped by 175429.54% to $472.4 billion in 2023, then plunged by 99.91% to $420.9 million in 2024, then retreated by 26.12% to $311.0 million in 2025, then rose by 1.31% to $315.0 million in 2026.
• Per Business Quant, the three latest EVH Receivables figures stand at $315.0 million (Q1 2026), $311.0 million (Q4 2025), and $408.1 million (Q3 2025).